---
Luna G, Alping P, Burman J et al. Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximabm and injectable therapies. JAMA Neurology2020; 77:184-91.var gaJsHost = (( " https: " == document.location.protocol) ? " https://ssl. " : " http://www. " ); document.write(unescape( " %3Cscript src= ' " + gaJsHost + " google-analytics.com/ga.js ' type= ' text/javascript ' %3E%3C/script%3E " ));var pageTracker = _gat._getTracker( " UA-3639768-12 " ); pageTracker._initData(); pageTracker._trackPageview();Swedish study examines risk of infections severe enough to caus...
Source: neurologyminutiae - November 22, 2020 Category: Neurology Source Type: blogs
MKSAP: 29-year-old woman is evaluated during a routine follow-up examination of multiple sclerosis
Test your medicine knowledge with the MKSAP challenge, in partnership with the American College of Physicians.
A 29-year-old woman is evaluated during a routine follow-up examination of multiple sclerosis, which was diagnosed 3 years ago. The patient says she wishes to discontinue her oral contraceptive and attempt to become pregnant. She has no other personal or family medical history of note. Medications are fingolimod, vitamin D, and an oral contraceptive.
On physical examination, temperature is 36.9 °C (98.5 °F), blood pressure is 100/50 mm Hg, pulse rate is 66/min, and respiration rate is 14/min; BMI is 27. A righ...
Source: Kevin, M.D. - Medical Weblog - June 2, 2018 Category: General Medicine Authors: < a href="https://www.kevinmd.com/blog/post-author/mksap" rel="tag" > mksap < /a > Tags: Conditions Neurology OB/GYN Source Type: blogs
A New Look at Phenotypic Screening
There have been several analyses that have suggested that phenotypic drug discovery was unusually effective in delivering "first in class" drugs. Now comes a reworking of that question, and these authors (Jörg Eder, Richard Sedrani, and Christian Wiesmann of Novartis) find plenty of room to question that conclusion.
What they've done is to deliberately focus on the first-in-class drug approvals from 1999 to 2013, and take a detailed look at their origins. There have been 113 such drugs, and they find that 78 of them (45 small molecules and 33 biologics) come from target-based approaches, and 35 from "systems-based" appro...
Source: In the Pipeline - August 26, 2014 Category: Chemists Tags: Drug Assays Source Type: blogs
Even Though Pharma Online Patient Support Campaigns Are Not Perfect, Patient Activists Bestow Honors Upon Them
The winners of the first Community Choice Awards, organized by WEGO Health, ExL Pharma, and the Digital Health Coalition, were announced last Friday (18 October 2013) at the Digital Pharma East Conference in Philadelphia."The event recognized healthcare organizations, teams, and individuals that have developed a unique offering and provide tangible value to their online patient communities," says WEGO Health in a press release. The awards consisted of seven categories: Best Unbranded Campaign, Best Branded Campaign, Best Non-Profit Partner, Company of the Year, Best Mobile Health App, Best Corporate Campaign, and Community...
Source: Pharma Marketing Blog - October 21, 2013 Category: Pharma Commentators Tags: Awards WEGO Gilenya patient support Merck Adverse events Twitter side effects Novartis Source Type: blogs
@GilenyaGoUSOnly: Another Rx Branded Twitter Account. Side Effects Sidebar is a Problem... Again!
Shame on me! I was unaware until today of @GilenyaGoUSOnly, an Rx-branded Twitter account run by Novartis, which markets Gilenya for the treatment of Multiple Sclerosis (MS). This Twitter account has been "active"since November 22, 2012, when it published its first tweet. To date the account has posted only 121 tweets (an average of 10 tweets per month), follows nobody, but has over 3,000 followers (I just became a follower this morning).For the record, here's a screenshot of the Twitter account (click on it for a full-sized view):When the FDA, this past August (29 AUG), issued a warning for patients who take Gilenya ...
Source: Pharma Marketing Blog - October 4, 2013 Category: Pharma Commentators Tags: Drug Safety PhRMA Guidelines Gilenya Novo Nordisk Race With Insulin DTC Advertising Twitter Risk Communication Novartis Source Type: blogs
FDA probe Gilenya
The US Food and Drug Administration (FDA) is investigating the potential link between Novartis' multiple sclerosis (MS) drug Gilenya and a rare brain infection.The investigation was launched after a patient treated with Gilenya (fingolimod) in Europe developed progressive multifocal leukoencephalopathy (PML) - an infection that has been associated with fellow MS drug Tysabri (natalizumab), which is marketed by Biogen Idec.Gilenya has already been linked to PML following a report last year that an MS patient taking the drug had developed the infection, although that patient had already received Tysabri earlier in ...
Source: PharmaGossip - September 3, 2013 Category: Pharma Commentators Authors: insider Source Type: blogs
Pharmalot... Pharmalittle... Good Morning
Hello, everyone, and how are you today? A shiny sun is hovering over the Pharmalot corporate campus, where are a cool breeze is wafting through the windows, and birds and bugs are offering a gloriously soothing cacophony of chitter chatter. As for us, we are busy doing the usual - reading documents and lining up interesting conversations. As always, we are helped along by a little cup of stimulation and, of course, we invite you to join us. Meanwhile, here are some tidbits. Have a great day and stay in touch...
Dr. Reddy's To Shift Toward More Brand-Name Drugs (Business Standard)
Glaxo Credit Outlook Cut To Negative By Moo...
Source: Pharmalot - July 30, 2013 Category: Pharma Commentators Authors: esilverman Source Type: blogs
Feds Probe Novartis Over Marketing Of Its Gilenya MS Pill
Novartis marketing is under a microscope. The US Attorney in New York has issued a civil investigative demand to the drugmaker for documents and information concerning its marketing practices for the Gilenya multiple sclerosis treatment. And the feds want to know about the “remuneration of health care providers,” which is another way of asking about how much money or goodies were given to doctors.
The move comes as Novartis faces a heated battle in the competitive multiple sclerosis market. A few months ago, Biogen began debuted its Tecfidera pill, which one analyst described at the time as the 'holy mother' of all dru...
Source: Pharmalot - July 18, 2013 Category: Pharma Commentators Authors: esilverman Source Type: blogs
Social Media Suggests An MS Dogfight Between Biogen And Novartis
Over the past month, surveying the track record for the newly launched Tecfidera multiple sclerosis pill has become a closely watched exercise on Wall Street. Each week, analysts pore over prescription data to gauge the extent to which the drug, which is sold by Biogen Idec, is capturing market share and how many billions of dollars in sales may be generated this year (back story).
Last week, for instance Tecfidera prescriptions rose 27 percent, a substantial increase, although less than the 37 percent gain noticed during the previous week. Not surprisingly, some of this reflects patients who are switching from older MS ...
Source: Pharmalot - May 23, 2013 Category: Pharma Commentators Authors: esilverman Source Type: blogs
Tecfidera's Price
Let us take up the case of Tecfidera, the new Biogen/Idec drug for multiple sclerosis, known to us chemists as dimethyl fumarate. It joins the (not very long) list of industrial chemicals (the kind that can be purchased in railroad-car sizes) that are also approved pharmaceuticals for human use. The MS area has seen this before, interestingly.
A year's supply of Tecfidera will set you (or your insurance company) back $54,900. That's a bit higher than many analysts were anticipating, but that means "a bit higher over $50,000". The ceiling is about $60,000, which is what Novartis's Gilenya (fingolomod) goes for, and Biogen ...
Source: In the Pipeline - April 2, 2013 Category: Chemists Tags: Drug Prices Source Type: blogs
New (to MS) Drug Approved for Multiple Sclerosis: The Price of Recycling
Good news for multiple sclerosis patients this week as the 10th disease modifying medication for MS (and the 3rd oral drug) was approved by the FDA. It’s not a new drug as a form of the medication has been approved for treatment of some types of psoriasis for nearly two decades. For a while it wasn’t even a drug – it was used an anti-mold treatment for sofas and shoes before its use was discontinued due to skin irritations. This week, however, Tecfidera (the drug many of us have known as “BG-12” during the testing phases) was approved and its maker, Biogen, intends to release the drug “within days”.
First bl...
Source: Life with MS - March 29, 2013 Category: Other Conditions Authors: admin Tags: MS treatment drug approval treatment cost Source Type: blogs
Teva Petitions FDA To Delay Biogen MS Drug
In the latest gambit by a drugmaker to derail a looming competitive threat, Teva Pharmaceuticals recently filed a citizen’s petition to ask the FDA not to approve a forthcoming multiple sclerosis treatment from Biogen Idec without first holding an advisory committee meeting.
For those who may not recall, Teva sells Copaxone, an injectable medicine that accounts for roughly 20 percent of revenue. This explains why the Israeli drugmaker – which is best known for selling generics, but wants to build a bigger brand-name business – is worried about Biogen and its BG-12 pill, which Wall Street thinks will be a...
Source: Pharmalot - January 10, 2013 Category: Pharma Commentators Authors: Ed Silverman Tags: Uncategorized Biogen Idec Gilenya MS Multiple Sclerosis Novartis Teva Pharmaceuticals Tysabri Source Type: blogs
